文献速递肾移植慢性肾脏病

多发性骨髓瘤CAR-T治疗后肾移植病例报告

Kidney Transplantation Post-Chimeric Antigen Receptor (CAR) T-Cell Therapy in Multiple Myeloma.
PubMed 文献 · Am J Kidney Dis · 2026-06-30

本文报告一例71岁III期多发性骨髓瘤伴高危细胞遗传学[del(17p)]患者,在透析依赖后接受BCMA定向CAR-T(cilta-cel)治疗达MRD阴性,1年后行活体肾移植,术后17个月移植肾功能稳定且血液学完全缓解。

要点

  • CAR-T治疗达MRD阴性后肾移植在多发性骨髓瘤中可行
  • 移植后需警惕低丙种球蛋白血症、血细胞减少、BK病毒血症和急性排斥
  • 个体化免疫抑制调整与支持治疗可维持移植肾功能稳定

核心结论

  • 多发性骨髓瘤患者经BCMA CAR-T治疗达深度缓解后行肾移植可行但存在挑战。

研究设计与样本

  • 单例病例报告:71岁男性III期多发性骨髓瘤伴del(17p),透析依赖,CAR-T后1年行活体肾移植。

主要发现

  • cilta-cel CAR-T治疗后达MRD阴性,移植后17个月移植肾功能稳定(肌酐1.8 mg/dL)且维持MRD阴性完全血液学缓解。
  • 移植后出现低丙种球蛋白血症、血细胞减少、BK病毒血症和急性排斥,经免疫抑制调整及支持治疗管理。

关键数值与推荐

  • 诱导方案为巴利昔单抗,维持免疫抑制为他克莫司/霉酚酸酯。

临床怎么用

  • 对CAR-T后达深度缓解的多发性骨髓瘤合并肾衰竭患者,可考虑肾移植但需多学科管理。
  • 移植后应监测低丙种球蛋白血症、血细胞减少、BK病毒及排斥反应。

局限性

  • 单例病例报告,结论外推需谨慎。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Kidney disease affects approximately half of patients with multiple myeloma (MM), and kidney failure is associated with poor prognosis. Kidney transplantation is rarely pursued in MM owing to concerns of relapse, infection, and allograft rejection. However, advances in therapy, including B-cell maturation antigen-directed chimeric antigen receptor (CAR) T-cell therapy, have led to deep and durable hematologic responses, creating new opportunities for transplantation in select patients. We report a 71-year-old man with stage III MM and high-risk cytogenetics [del(17p)] who developed end-stage kidney disease requiring hemodialysis during his treatment course. Despite multiple lines of therapy, he had never achieved a deep remission until he received ciltacabtagene autoleucel (cilta-cel) CAR T-cell therapy, which led to minimal residual disease (MRD)-negative disease status. One year following CAR T-cell therapy, he underwent living donor kidney transplantation with basiliximab induction, and tacrolimus/mycophenolate maintenance immunosuppression. His course was complicated by hypogammaglobulinemia, cytopenia, BK viremia, and acute rejection, all managed with immunosuppression adjustment and supportive therapies. At 17 months post-transplant, allograft function remains stable (creatinine 1.8 mg/dL), and he has achieved an MRD-negative, complete hematologic remission. This case highlights both the feasibility and the challenges of kidney transplantation after CAR T-cell therapy in MM.

来源:Am J Kidney Dis,查看原文。版权归原作者所有。

引用

  1. Khan Z, Dadhania DM, Brailovski E, et al. Kidney Transplantation Post-Chimeric Antigen Receptor (CAR) T-Cell Therapy in Multiple Myeloma. Am J Kidney Dis. 2026. PMID: 42379467. doi:10.1053/j.ajkd.2026.04.012

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。